

## News from other Hematologic Malignancies

### **Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.**

*Meletios A. Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.*

**Conclusions:** The IR combination demonstrated superior efficacy to R, producing significant improvements in PFS for all WM patients regardless of prognostic or genotypic factors with a predictable toxicity profile. IR should be considered a standard therapeutic option for patients with WM. Clinical trial information: [NCT02165397](https://clinicaltrials.gov/ct2/show/study/NCT02165397)

[J Clin Oncol 36, 2018 \(suppl; abstr 8003\)](#)

[SEE ALSO PUBLICATION IN THE NEJM](#)